Kevin Moran Biography and Net Worth

CFO of Vanda Pharmaceuticals

Kevin Moran has served as our Senior Vice President, Chief Financial Officer and Treasurer, since March 2020. Prior to that, Mr. Moran served as our Vice President and Controller from March 2018 to March 2020, our Controller from December 2012 until March 2018 and in other finance roles at the Company between September 2010 and December 2012. Prior to that, Mr. Moran was a Senior Associate at PricewaterhouseCoopers, an independent registered public accounting firm. Mr. Moran earned his Bachelor of Business Administration and his Master of Science in Accounting from James Madison University.

What is Kevin Patrick Moran's net worth?: The estimated net worth of Kevin Patrick Moran is at least $550,455.84 as of July 28th, 2023. Mr. Moran owns 120,714 shares of Vanda Pharmaceuticals stock worth more than $550,456 as of April 25th. This net worth approximation does not reflect any other assets that Mr. Moran may own. Additionally, Mr. Moran receives an annual salary of $660,220.00 as CFO at Vanda Pharmaceuticals. Learn More about Kevin Patrick Moran's net worth.
How old is Kevin Patrick Moran?: Mr. Moran is currently 39 years old. There are 4 older executives and no younger executives at Vanda Pharmaceuticals. The oldest executive at Vanda Pharmaceuticals is Dr. Mihael H. Polymeropoulos M.D., Founder, President, CEO & Chairman of The Board, who is 64 years old. Learn More on Kevin Patrick Moran's age.
What is Kevin Patrick Moran's salary?: As the CFO of Vanda Pharmaceuticals Inc., Mr. Moran earns $660,220.00 per year. There are 4 executives that earn more than Mr. Moran. The highest earning executive at Vanda Pharmaceuticals is Dr. Mihael H. Polymeropoulos M.D., Founder, President, CEO & Chairman of The Board, who commands a salary of $1,510,000.00 per year. Learn More on Kevin Patrick Moran's salary.
How do I contact Kevin Patrick Moran?: The corporate mailing address for Mr. Moran and other Vanda Pharmaceuticals executives is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. Vanda Pharmaceuticals can also be reached via phone at (202) 734-3400 and via email at [email protected]. Learn More on Kevin Patrick Moran's contact information.
Has Kevin Patrick Moran been buying or selling shares of Vanda Pharmaceuticals?: Kevin Patrick Moran has not been actively trading shares of Vanda Pharmaceuticals during the last ninety days. Most recently, Kevin Patrick Moran sold 2,212 shares of the business's stock in a transaction on Friday, July 28th. The shares were sold at an average price of $6.30, for a transaction totalling $13,935.60. Following the completion of the sale, the chief financial officer now directly owns 120,714 shares of the company's stock, valued at $760,498.20. Learn More on Kevin Patrick Moran's trading history.
Who are Vanda Pharmaceuticals' active insiders?: Vanda Pharmaceuticals' insider roster includes Phaedra Chrousos (Director), Aranthan Jones, II (Insider), Stephen Mitchell (Director), Kevin Moran (CFO), Mihael Polymeropoulos (CEO), and Joakim Wijkstrom (CMO). Learn More on Vanda Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vanda Pharmaceuticals?: In the last twelve months, insiders at the biopharmaceutical company sold shares 5 times. They sold a total of 43,036 shares worth more than $271,424.76. The most recent insider tranaction occured on August, 21st when CMO Joakim Wijkstrom sold 3,724 shares worth more than $21,748.16. Insiders at Vanda Pharmaceuticals own 7.7% of the company. Learn More about insider trades at Vanda Pharmaceuticals.
Information on this page was last updated on 8/21/2023.

Kevin Patrick Moran Insider Trading History at Vanda Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/28/2023	Sell	2,212	$6.30	$13,935.60	120,714
6/15/2023	Sell	16,000	$6.29	$100,640.00	122,926
3/2/2023	Sell	7,966	$6.26	$49,867.16	144,894
12/6/2022	Sell	4,792	$10.61	$50,843.12	120,160
7/28/2022	Sell	2,239	$10.97	$24,561.83	117,452
3/1/2022	Sell	3,473	$11.19	$38,862.87
7/28/2021	Sell	2,130	$19.24	$40,981.20	99,296

Kevin Patrick Moran Buying and Selling Activity at Vanda Pharmaceuticals

Vanda Pharmaceuticals Company Overview

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Today's Range

Now: $4.56

$4.56

50 Day Range

MA: $4.27

$3.75

$5.24

2 Week Range

Now: $4.56

$3.30

$7.00

Volume

12,510 shs

Average Volume

2,052,841 shs

Market Capitalization

$262.38 million

P/E Ratio

91.22

Dividend Yield

N/A

Beta

0.76

Global crypto currency reset (41 major banks signed up)

From Stansberry Research | Ad

Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...

Here's everything you need to know.

Kevin Moran Biography and Net Worth

What is Kevin Patrick Moran's net worth?

How old is Kevin Patrick Moran?

What is Kevin Patrick Moran's salary?

How do I contact Kevin Patrick Moran?

Has Kevin Patrick Moran been buying or selling shares of Vanda Pharmaceuticals?

Who are Vanda Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Vanda Pharmaceuticals?